GAA
REGN icon

Green Alpha Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Green Alpha Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-341
Closed -$213K – 116
2026
Q2 		$213K Buy
341
+5
+1% +$3.4K 0.14% 101
2026
Q1 		$260K Sell
336
-45
-12% -$34.5K 0.26% 82
2025
Q4 		$294K Buy
+381
New +$259K 0.27% 88
2025
Q2 		– Sell
-344
Closed -$218K – 110
2025
Q1 		$218K Sell
344
-14
-4% -$9.63K 0.23% 92
2024
Q4 		$255K Sell
358
-24
-6% -$20.1K 0.2% 118
2024
Q3 		$402K Sell
382
-34
-8% -$37.8K 0.32% 99
2024
Q2 		$437K Sell
416
-52
-11% -$50.4K 0.35% 95
2024
Q1 		$450K Buy
468
+7
+2% +$6.66K 0.33% 105
2023
Q4 		$405K Sell
461
-71
-13% -$58.5K 0.29% 119
2023
Q3 		$438K Buy
+532
New +$418K 0.34% 99

Other funds holding REGN

GA
GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return
WC
Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return
SBWIC
Schaper Benz & Wise Investment Counsel Neenah, Wisconsin $1.51B AUM 27.44% 1-Year Est. Return
NPPM
North Point Portfolio Managers Orange Village, Ohio $595M AUM 14.89% 1-Year Est. Return

Green Alpha Advisors's REGN Position: Q3 2026 in Review

Green Alpha Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q3 2026, closing a stake of 341 shares — an estimated $213K sold.

Green Alpha Advisors first reported a position in REGN in Q3 2023 and held it in 10 quarters. The position peaked at $450K in Q1 2024. 122 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Green Alpha Advisors reported no remaining Regeneron Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Green Alpha Advisors sold 341 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $213K.
  • Green Alpha Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2023 and held it in 10 quarters.
  • Green Alpha Advisors's Regeneron Pharmaceuticals position peaked at $450K in Q1 2024.
  • 122 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Green Alpha Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.